Form 4: Pacific Biosciences Director Marshall Mohr Granted 65,000 Stock Options

Pacific Biosciences of California, Inc. Director Marshall Mohr was granted 65,000 stock options with an exercise price of $1.03, vesting over one year.

Summary

• Marshall Mohr, a Director of Pacific Biosciences of California, Inc. (PACB), was granted 65,000 stock options.
• The options have an exercise price of $1.03 per share.
• The options were granted on June 4, 2025, and become exercisable starting July 4, 2025.
• The options expire on June 4, 2035.
• The underlying securities are 65,000 shares of Common Stock.
• The shares subject to the option will vest monthly over one year, or earlier on the date of the next annual meeting, contingent on continued service as a director.
• Marshall Mohr has granted a Power of Attorney to several individuals to file Section 16 forms on his behalf.

Sentiment

Score: 6

Explanation: The document reports a routine stock option grant to a director, which is a neutral to slightly positive event as it aligns management incentives with shareholder value, but does not indicate significant operational or financial news.

Positives

• Grant of 65,000 stock options to Director Marshall Mohr, aligning his interests with shareholder value.
• The options have a 10-year expiration date (June 4, 2035), providing a long window for potential exercise.

Future Outlook

Not applicable. This document is an insider transaction report and does not contain forward-looking statements or guidance.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, specifically the grant of stock options to a director. Such grants are common practice in the biotechnology and broader corporate sectors as a form of executive and director compensation, aiming to align the interests of management with those of shareholders.

Corporate Governance

Related Party Transactions

• Grant of 65,000 stock options to Marshall Mohr, a Director of Pacific Biosciences of California, Inc., as part of his compensation package.

Stakeholder Impact

• Shareholders: The grant of stock options to a director aligns management's interests with shareholder value, as the options gain value if the stock price increases.

Next Steps

• The stock options will vest monthly over one year, contingent on Marshall Mohr's continued service as a director.

Key Dates

Keywords

Pacific Biosciences, PACB, Marshall Mohr, Stock Option Grant, Form 4, SEC Filing, Director Compensation, Equity Compensation, Insider Transaction, Biotechnology, Genomics